Hematopoietic stem cell transplant–associated thrombotic microangiopathy: review of pharmacologic treatment options

Abstract excerpt

BACKGROUND: Transplant-associated thrombotic microangiopathy (TA-TMA) is a multifactorial disorder, which occurs as a result of treatment-related endothelial injury and underlying disease process after hematopoietic stem cell transplantation (HSCT). The reported incidence of TA-TMA after HSCT is 0% to 74% and has shown to be associated with mortality rate of up to 100%. TA-TMA is often diagnosed late in the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Chemotherapy-induced cardiotoxicity and mitigation
• Share to Complement system in diseases